- Home
- GORV vs BLRX Comparison
GORV vs BLRX Comparison
Compare GORV & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- BLRX
- Stock Information
- Founded
- GORV 1976
- BLRX 2003
- Country
- GORV United States
- BLRX Israel
- Employees
- GORV N/A
- BLRX N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- BLRX Health Care
- Exchange
- GORV Nasdaq
- BLRX Nasdaq
- Market Cap
- GORV 15.5M
- BLRX 17.0M
- IPO Year
- GORV 2015
- BLRX 2011
- Fundamental
- Price
- GORV $2.94
- BLRX $3.77
- Analyst Decision
- GORV
- BLRX Strong Buy
- Analyst Count
- GORV 0
- BLRX 2
- Target Price
- GORV N/A
- BLRX $19.00
- AVG Volume (30 Days)
- GORV 52.5K
- BLRX 39.6K
- Earning Date
- GORV 08-14-2025
- BLRX 08-14-2025
- Dividend Yield
- GORV N/A
- BLRX N/A
- EPS Growth
- GORV N/A
- BLRX N/A
- EPS
- GORV N/A
- BLRX N/A
- Revenue
- GORV $662,952,000.00
- BLRX $17,251,000.00
- Revenue This Year
- GORV $15.65
- BLRX N/A
- Revenue Next Year
- GORV $20.54
- BLRX N/A
- P/E Ratio
- GORV N/A
- BLRX N/A
- Revenue Growth
- GORV N/A
- BLRX 1.19
- 52 Week Low
- GORV $2.52
- BLRX $2.30
- 52 Week High
- GORV $58.80
- BLRX $27.20
- Technical
- Relative Strength Index (RSI)
- GORV 24.38
- BLRX 45.15
- Support Level
- GORV $3.46
- BLRX $3.46
- Resistance Level
- GORV $4.05
- BLRX $3.92
- Average True Range (ATR)
- GORV 0.41
- BLRX 0.24
- MACD
- GORV 0.02
- BLRX 0.02
- Stochastic Oscillator
- GORV 17.80
- BLRX 57.14
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.